Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 18 | 6 | 24 |
| 1996 | 27 | 3 | 30 |
| 1997 | 23 | 1 | 24 |
| 1998 | 21 | 8 | 29 |
| 1999 | 20 | 9 | 29 |
| 2000 | 21 | 9 | 30 |
| 2001 | 25 | 18 | 43 |
| 2002 | 22 | 10 | 32 |
| 2003 | 27 | 8 | 35 |
| 2004 | 25 | 15 | 40 |
| 2005 | 33 | 9 | 42 |
| 2006 | 27 | 13 | 40 |
| 2007 | 24 | 17 | 41 |
| 2008 | 37 | 7 | 44 |
| 2009 | 33 | 13 | 46 |
| 2010 | 37 | 9 | 46 |
| 2011 | 54 | 16 | 70 |
| 2012 | 41 | 18 | 59 |
| 2013 | 30 | 16 | 46 |
| 2014 | 50 | 13 | 63 |
| 2015 | 41 | 20 | 61 |
| 2016 | 48 | 17 | 65 |
| 2017 | 36 | 15 | 51 |
| 2018 | 48 | 19 | 67 |
| 2019 | 70 | 14 | 84 |
| 2020 | 46 | 20 | 66 |
| 2021 | 45 | 37 | 82 |
| 2022 | 12 | 48 | 60 |
| 2023 | 3 | 49 | 52 |
| 2024 | 36 | 38 | 74 |
| 2025 | 6 | 3 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025 Apr 01; 31(7):1233-1242.
-
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13; 145(11):1126-1135.
-
Trends in complexity of single-agent and combination therapies for solid tumor cancers approved by the US Food and Drug Administration. Oncologist. 2025 Mar 10; 30(3).
-
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study. Cancer. 2025 Feb 15; 131(4):e35750.
-
Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial. Ann Surg Oncol. 2025 May; 32(5):3278-3291.
-
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
-
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025 Mar; 194:18-24.
-
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025 Feb 06; 145(6):577-589.
-
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. Clin Cancer Res. 2025 Jan 17; 31(2):299-307.
-
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025 Jan 11; 405(10473):127-136.